Communiqués Gritstone bio, Inc.

Actions

GRTS

US39868T1051

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/06/2024			Varia. 5j.	Varia. 1 janv.
0,7734 ^USD	+0,72 %		+3,62 %	-62,09 %

24/05	GRITSTONE BIO, INC. : Opinion positive de B. Riley	ZM
09/05	Transcript : Gritstone bio, Inc., Q1 2024 Earnings Call, May 09, 2024

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	04/06	AQ
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates	09/05	GL
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024	02/05	AQ
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024	30/04	AQ
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors	29/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	20/04	PR
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform	16/04	AQ
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)	15/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	12/04	PR
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	08/04	AQ
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024	08/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	05/04	PR
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering	02/04	AQ
Gritstone bio Announces Proposed Public Offering	01/04	AQ
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	01/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	19/03	PR
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	05/03	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	05/03	PR
Gritstone bio Announces Workforce Reduction	29/02	AQ
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	21/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Gritstone bio, Inc.

Actions

GRTS

US39868T1051

Communiqués

Filtres